Ash Stevens, Incorporated (ASI), a full service contract drug development and cGMP manufacturer, announced that the company is in the initial phases of a multi-year $6 million expansion project to upgrade the capacity and capabilities of its Active Pharmaceutical Ingredient (API) manufacturing facility located in Riverview, Michigan. Expansions will include a new reactor bay and warehouse.
Detroit, MI (PRWEB) September 30, 2009 -- Ash Stevens, Incorporated (ASI), a full service contract drug development and cGMP manufacturer, announced that the company is in the initial phases of a multi-year expansion project to upgrade the capacity and capabilities of its Active Pharmaceutical Ingredient (API) manufacturing facility located in Riverview, Michigan. Expenditures for the initial phases of the project will total more than $6 million and will include a new reactor bay and warehouse. The investment will add significant capacity and additional capabilities to the existing ASI facility as part of ASI's on-going commitment to provide the company's clients with the highest quality of service, safety, and on-time delivery of APIs.
To be operational in January 2010, the plan's initial phase calls for an isolated new reactor bay, which will house two 100-gallon glass-lined reactors and a 50-gallon hydrogenation vessel. The new reactor bay will provide redundant capacity to a similarly designed existing bay that holds three 100-gallon reactors, while providing additional plant capacity and plant-scale hydrogenation capabilities.
In June of 2010, ASI will occupy a new 10,000 square foot warehouse facility. Completion of the state-of-the-art reactor bay and warehouse facility will set the stage for execution of the next phases of the expansion plan.
"The new bay and warehouse represent a self-financed $6 million investment for ASI. The continuous upgrading and modernization of our operations is an essential component of our business model to provide our clients the highest quality of service while ensuring delivery of their API on time and on schedule from a safe and environmentally friendly facility. As we increase our efficiencies with larger equipment, we also enhance our cost-effectiveness, further benefiting our customers," said Dr. Stephen Munk, President and CEO of Ash Stevens.
Subsequent phases of the expansion plan call for a new large-scale reactor bay, process development labs, and additional facilities to handle highly potent APIs.
For more information, visit Ash Stevens at CPhI Worldwide in Madrid, Spain, booth #NB403 located in the New Business Pavillion on October 16-19, 2009 or online at www.ashstevens.com. James M. Hamby, R.Ph., Ph.D., Vice President of Business Development for Ash Stevens, Inc. will be speaking on the topic of Managing CMC Development for FDA Fast-Tracked Drugs on Tuesday, October 13 at 2:00 p.m.
About Ash Stevens, Inc.
Headquartered in Detroit, Ash Stevens, Inc. (ASI) was founded in 1962 to service the chemical research needs of the Federal Government. ASI has extensive experience in the development and scale-up of commercial cancer APIs and shares a longstanding and successful relationship with the National Cancer Institute. ASI has a total of 11 FDA approved drug substances in its portfolio. The company has more than 60 employees and holds a variety of patents covering topics including medicinal agents and manufacturing processes. For more information, visit www.ashstevens.com.
Read the full story at http://www.prweb.com/releases/2009/09/prweb2966284.htm.
Copyright©2009 Vocus, Inc.
All rights reserved